Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$15.80 USD
+0.22 (1.41%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $15.78 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.80 USD
+0.22 (1.41%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $15.78 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 80.3% in Perspective Therapeutics (CATX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Perspective Therapeutics (CATX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Perspective Therapeutics (CATX) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -3.70% and 6.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.28% and 9.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?